Takeda Pharmaceutical Company Limited (NYSE: TAK) Stock Competitors & Peer Comparison
See TAK's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for TAK and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| TAK | $19.61 | -0.31% | 62.4B | 14.10 | $1.39 | +3.59% |
| TEVA | $41.31 | -0.46% | 48.1B | 14.09 | $2.93 | N/A |
| HLN | $10.14 | +0.10% | 44.6B | 20.77 | $0.49 | +1.95% |
| ZTS | $79.59 | +0.26% | 32.9B | 12.09 | $6.58 | +2.62% |
| VTRS | $18.26 | -2.12% | 21B | 7.25 | $2.52 | +2.64% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $23.49 | -0.25% | 11.7B | 22.15 | $1.06 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $13.08 | +0.08% | 10.9B | 27.85 | $0.47 | +0.64% |
| ALKS | $42.97 | +4.25% | 7.2B | 45.23 | $0.95 | N/A |
Stock Comparison
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
TAK vs TEVA Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, TEVA has a market cap of 48.1B. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while TEVA trades at $41.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas TEVA's P/E ratio is 14.09. In terms of profitability, TAK's ROE is +0.02%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, TAK is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for TAK.Check TEVA's competition here
Haleon plc (NYSE: HLN)
TAK vs HLN Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, HLN has a market cap of 44.6B. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while HLN trades at $10.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas HLN's P/E ratio is 20.77. In terms of profitability, TAK's ROE is +0.02%, compared to HLN's ROE of +0.10%. Regarding short-term risk, TAK is less volatile compared to HLN. This indicates lower risk in terms of short-term price fluctuations for TAK.Check HLN's competition here
Zoetis Inc. (NYSE: ZTS)
TAK vs ZTS Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, ZTS has a market cap of 32.9B. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while ZTS trades at $79.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas ZTS's P/E ratio is 12.09. In terms of profitability, TAK's ROE is +0.02%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, TAK is less volatile compared to ZTS. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
TAK vs VTRS Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, VTRS has a market cap of 21B. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while VTRS trades at $18.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas VTRS's P/E ratio is 7.25. In terms of profitability, TAK's ROE is +0.02%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, TAK is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for TAK.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
TAK vs ITCI Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas ITCI's P/E ratio is -180.64. In terms of profitability, TAK's ROE is +0.02%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, TAK is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for TAK.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
TAK vs ELAN Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, ELAN has a market cap of 11.7B. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while ELAN trades at $23.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas ELAN's P/E ratio is 22.15. In terms of profitability, TAK's ROE is +0.02%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, TAK is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ELAN's competition here
Catalent, Inc. (NYSE: CTLT)
TAK vs CTLT Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas CTLT's P/E ratio is -27.84. In terms of profitability, TAK's ROE is +0.02%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, TAK is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for TAK.Check CTLT's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
TAK vs RDY Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, RDY has a market cap of 10.9B. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while RDY trades at $13.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas RDY's P/E ratio is 27.85. In terms of profitability, TAK's ROE is +0.02%, compared to RDY's ROE of +0.09%. Regarding short-term risk, TAK is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for TAK.Check RDY's competition here
Alkermes plc (NASDAQ: ALKS)
TAK vs ALKS Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, ALKS has a market cap of 7.2B. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while ALKS trades at $42.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas ALKS's P/E ratio is 45.23. In terms of profitability, TAK's ROE is +0.02%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, TAK is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ALKS's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
TAK vs LNTH Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, LNTH has a market cap of 6.5B. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while LNTH trades at $99.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas LNTH's P/E ratio is 16.79. In terms of profitability, TAK's ROE is +0.02%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, TAK is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for TAK.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
TAK vs AMRX Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, AMRX has a market cap of 6.2B. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while AMRX trades at $19.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas AMRX's P/E ratio is 21.51. In terms of profitability, TAK's ROE is +0.02%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, TAK is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for TAK.Check AMRX's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
TAK vs RGC Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, RGC has a market cap of 5B. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while RGC trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas RGC's P/E ratio is -1005.00. In terms of profitability, TAK's ROE is +0.02%, compared to RGC's ROE of -1.61%. Regarding short-term risk, TAK is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for TAK.Check RGC's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
TAK vs INDV Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, INDV has a market cap of 4.2B. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while INDV trades at $33.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas INDV's P/E ratio is 9.28. In terms of profitability, TAK's ROE is +0.02%, compared to INDV's ROE of -2.16%. Regarding short-term risk, TAK is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for TAK.Check INDV's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
TAK vs HCM Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, HCM has a market cap of 2.5B. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while HCM trades at $14.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas HCM's P/E ratio is 137.14. In terms of profitability, TAK's ROE is +0.02%, compared to HCM's ROE of +0.01%. Regarding short-term risk, TAK is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for TAK.Check HCM's competition here
Alvotech (NASDAQ: ALVOW)
TAK vs ALVOW Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, ALVOW has a market cap of 2.4B. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while ALVOW trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas ALVOW's P/E ratio is 37.90. In terms of profitability, TAK's ROE is +0.02%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, TAK is more volatile compared to ALVOW. This indicates higher risk in terms of short-term price fluctuations for TAK.Check ALVOW's competition here
Bausch Health Companies Inc. (NYSE: BHC)
TAK vs BHC Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, BHC has a market cap of 2.4B. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while BHC trades at $6.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas BHC's P/E ratio is 1.62. In terms of profitability, TAK's ROE is +0.02%, compared to BHC's ROE of +0.89%. Regarding short-term risk, TAK is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for TAK.Check BHC's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
TAK vs SUPN Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, SUPN has a market cap of 2.3B. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while SUPN trades at $39.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas SUPN's P/E ratio is 13.02. In terms of profitability, TAK's ROE is +0.02%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, TAK is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for TAK.Check SUPN's competition here
Perrigo Company plc (NYSE: PRGO)
TAK vs PRGO Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, PRGO has a market cap of 2.2B. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while PRGO trades at $16.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas PRGO's P/E ratio is 6.44. In terms of profitability, TAK's ROE is +0.02%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, TAK is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for TAK.Check PRGO's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
TAK vs DCPH Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas DCPH's P/E ratio is -11.58. In terms of profitability, TAK's ROE is +0.02%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, TAK is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for TAK.Check DCPH's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
TAK vs AVDL Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, TAK's ROE is +0.02%, compared to AVDL's ROE of +0.10%. Regarding short-term risk, TAK is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for TAK.Check AVDL's competition here
Embecta Corp. (NASDAQ: EMBCV)
TAK vs EMBCV Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas EMBCV's P/E ratio is N/A. In terms of profitability, TAK's ROE is +0.02%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, TAK is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for TAK.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
TAK vs DVAX Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas DVAX's P/E ratio is -41.89. In terms of profitability, TAK's ROE is +0.02%, compared to DVAX's ROE of +0.09%. Regarding short-term risk, TAK is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for TAK.Check DVAX's competition here
Alvotech (NASDAQ: ALVO)
TAK vs ALVO Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, ALVO has a market cap of 1.8B. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while ALVO trades at $5.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas ALVO's P/E ratio is -8.53. In terms of profitability, TAK's ROE is +0.02%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, TAK is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ALVO's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
TAK vs TRLV Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, TRLV has a market cap of 1.7B. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while TRLV trades at $10.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas TRLV's P/E ratio is -4.18. In terms of profitability, TAK's ROE is +0.02%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, TAK is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for TAK.Check TRLV's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
TAK vs ANIP Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while ANIP trades at $72.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas ANIP's P/E ratio is 8.84. In terms of profitability, TAK's ROE is +0.02%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, TAK is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for TAK.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
TAK vs TARO Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas TARO's P/E ratio is 30.05. In terms of profitability, TAK's ROE is +0.02%, compared to TARO's ROE of +0.03%. Regarding short-term risk, TAK is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for TAK.Check TARO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
TAK vs PAHC Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, PAHC has a market cap of 1.6B. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while PAHC trades at $39.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas PAHC's P/E ratio is 13.42. In terms of profitability, TAK's ROE is +0.02%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, TAK is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for TAK.Check PAHC's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
TAK vs PCRX Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, PCRX has a market cap of 1.4B. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while PCRX trades at $36.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas PCRX's P/E ratio is 13.98. In terms of profitability, TAK's ROE is +0.02%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, TAK is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for TAK.Check PCRX's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
TAK vs ETON Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, ETON has a market cap of 1.4B. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while ETON trades at $49.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas ETON's P/E ratio is 129.50. In terms of profitability, TAK's ROE is +0.02%, compared to ETON's ROE of +0.40%. Regarding short-term risk, TAK is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ETON's competition here
Cronos Group Inc. (NASDAQ: CRON)
TAK vs CRON Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while CRON trades at $3.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas CRON's P/E ratio is 16.64. In terms of profitability, TAK's ROE is +0.02%, compared to CRON's ROE of +0.06%. Regarding short-term risk, TAK is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for TAK.Check CRON's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
TAK vs AMPH Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, AMPH has a market cap of 1.1B. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while AMPH trades at $26.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas AMPH's P/E ratio is 8.92. In terms of profitability, TAK's ROE is +0.02%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, TAK is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for TAK.Check AMPH's competition here
Harrow Health, Inc. (NASDAQ: HROW)
TAK vs HROW Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, HROW has a market cap of 1B. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while HROW trades at $27.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas HROW's P/E ratio is -27.96. In terms of profitability, TAK's ROE is +0.02%, compared to HROW's ROE of -1.04%. Regarding short-term risk, TAK is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for TAK.Check HROW's competition here
PetIQ, Inc. (NASDAQ: PETQ)
TAK vs PETQ Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas PETQ's P/E ratio is 83.73. In terms of profitability, TAK's ROE is +0.02%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, TAK is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for TAK.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
TAK vs COLL Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, COLL has a market cap of 749.1M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while COLL trades at $23.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas COLL's P/E ratio is 2.89. In terms of profitability, TAK's ROE is +0.02%, compared to COLL's ROE of +0.16%. Regarding short-term risk, TAK is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for TAK.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
TAK vs IRWD Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, IRWD has a market cap of 584.9M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while IRWD trades at $3.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas IRWD's P/E ratio is 4.54. In terms of profitability, TAK's ROE is +0.02%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, TAK is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for TAK.Check IRWD's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
TAK vs BDSI Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas BDSI's P/E ratio is 6.82. In terms of profitability, TAK's ROE is +0.02%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, TAK is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for TAK.Check BDSI's competition here
Evotec SE (NASDAQ: EVO)
TAK vs EVO Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, EVO has a market cap of 504.4M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while EVO trades at $1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas EVO's P/E ratio is -2.01. In terms of profitability, TAK's ROE is +0.02%, compared to EVO's ROE of -0.27%. Regarding short-term risk, TAK is less volatile compared to EVO. This indicates lower risk in terms of short-term price fluctuations for TAK.Check EVO's competition here
Evolus, Inc. (NASDAQ: EOLS)
TAK vs EOLS Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, EOLS has a market cap of 486.1M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while EOLS trades at $7.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas EOLS's P/E ratio is -23.31. In terms of profitability, TAK's ROE is +0.02%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, TAK is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for TAK.Check EOLS's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
TAK vs AQST Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, AQST has a market cap of 480.7M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while AQST trades at $3.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas AQST's P/E ratio is -5.89. In terms of profitability, TAK's ROE is +0.02%, compared to AQST's ROE of +2.44%. Regarding short-term risk, TAK is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for TAK.Check AQST's competition here
Kamada Ltd. (NASDAQ: KMDA)
TAK vs KMDA Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, KMDA has a market cap of 439.1M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while KMDA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas KMDA's P/E ratio is 20.03. In terms of profitability, TAK's ROE is +0.02%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, TAK is less volatile compared to KMDA. This indicates lower risk in terms of short-term price fluctuations for TAK.Check KMDA's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
TAK vs TKNO Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, TKNO has a market cap of 365.1M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while TKNO trades at $6.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas TKNO's P/E ratio is -21.94. In terms of profitability, TAK's ROE is +0.02%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, TAK is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for TAK.Check TKNO's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
TAK vs TLRY Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, TLRY has a market cap of 338.8M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while TLRY trades at $3.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas TLRY's P/E ratio is -2.16. In terms of profitability, TAK's ROE is +0.02%, compared to TLRY's ROE of -0.09%. Regarding short-term risk, TAK is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for TAK.Check TLRY's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
TAK vs EBS Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, EBS has a market cap of 325.8M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while EBS trades at $6.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas EBS's P/E ratio is 4.41. In terms of profitability, TAK's ROE is +0.02%, compared to EBS's ROE of -0.36%. Regarding short-term risk, TAK is less volatile compared to EBS. This indicates lower risk in terms of short-term price fluctuations for TAK.Check EBS's competition here
Canopy Growth Corporation (NASDAQ: CGC)
TAK vs CGC Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, CGC has a market cap of 302.8M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while CGC trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas CGC's P/E ratio is -1.60. In terms of profitability, TAK's ROE is +0.02%, compared to CGC's ROE of -0.33%. Regarding short-term risk, TAK is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for TAK.Check CGC's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
TAK vs ALIM Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas ALIM's P/E ratio is 5.28. In terms of profitability, TAK's ROE is +0.02%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, TAK is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for TAK.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
TAK vs LNDC Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas LNDC's P/E ratio is -4.04. In terms of profitability, TAK's ROE is +0.02%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, TAK is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for TAK.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
TAK vs ACB Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, ACB has a market cap of 251.3M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while ACB trades at $3.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas ACB's P/E ratio is -2.87. In terms of profitability, TAK's ROE is +0.02%, compared to ACB's ROE of -0.21%. Regarding short-term risk, TAK is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ACB's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
TAK vs LFCR Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, LFCR has a market cap of 242.4M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while LFCR trades at $6.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas LFCR's P/E ratio is -5.04. In terms of profitability, TAK's ROE is +0.02%, compared to LFCR's ROE of -3.77%. Regarding short-term risk, TAK is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for TAK.Check LFCR's competition here
Shineco, Inc. (NASDAQ: TYHT)
TAK vs TYHT Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas TYHT's P/E ratio is -1.61. In terms of profitability, TAK's ROE is +0.02%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, TAK is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for TAK.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
TAK vs SIGA Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, SIGA has a market cap of 225.6M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while SIGA trades at $3.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas SIGA's P/E ratio is 11.63. In terms of profitability, TAK's ROE is +0.02%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, TAK is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for TAK.Check SIGA's competition here
Glass House Brands Inc (NYSE: GLAS)
TAK vs GLAS Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, GLAS has a market cap of 214.7M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while GLAS trades at $2.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas GLAS's P/E ratio is -4.36. In terms of profitability, TAK's ROE is +0.02%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, TAK is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for TAK.Check GLAS's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
TAK vs REPH Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas REPH's P/E ratio is -8.04. In terms of profitability, TAK's ROE is +0.02%, compared to REPH's ROE of -0.22%. Regarding short-term risk, TAK is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for TAK.Check REPH's competition here
Theratechnologies Inc. (NASDAQ: THTX)
TAK vs THTX Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas THTX's P/E ratio is -28.83. In terms of profitability, TAK's ROE is +0.02%, compared to THTX's ROE of +0.36%. Regarding short-term risk, TAK is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for TAK.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
TAK vs ASRT Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas ASRT's P/E ratio is -7.10. In terms of profitability, TAK's ROE is +0.02%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, TAK is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for TAK.Check ASRT's competition here
Journey Medical Corporation (NASDAQ: DERM)
TAK vs DERM Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, DERM has a market cap of 146.2M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while DERM trades at $5.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas DERM's P/E ratio is -23.55. In terms of profitability, TAK's ROE is +0.02%, compared to DERM's ROE of -0.20%. Regarding short-term risk, TAK is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for TAK.Check DERM's competition here
Organigram Global Inc. (NASDAQ: OGI)
TAK vs OGI Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, OGI has a market cap of 133.3M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while OGI trades at $0.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas OGI's P/E ratio is 2.12. In terms of profitability, TAK's ROE is +0.02%, compared to OGI's ROE of +0.21%. Regarding short-term risk, TAK is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for TAK.Check OGI's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
TAK vs CRDL Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, CRDL has a market cap of 132.7M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while CRDL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas CRDL's P/E ratio is -4.38. In terms of profitability, TAK's ROE is +0.02%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, TAK is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for TAK.Check CRDL's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
TAK vs ORGO Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, ORGO has a market cap of 131.2M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while ORGO trades at $1.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas ORGO's P/E ratio is 34.00. In terms of profitability, TAK's ROE is +0.02%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, TAK is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ORGO's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
TAK vs SCTL Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas SCTL's P/E ratio is -7.86. In terms of profitability, TAK's ROE is +0.02%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, TAK is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for TAK.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
TAK vs BGM Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, BGM has a market cap of 108.3M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while BGM trades at $8.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas BGM's P/E ratio is -1.78. In terms of profitability, TAK's ROE is +0.02%, compared to BGM's ROE of -0.05%. Regarding short-term risk, TAK is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for TAK.Check BGM's competition here
Procaps Group S.A. (NASDAQ: PROC)
TAK vs PROC Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas PROC's P/E ratio is 1.53. In terms of profitability, TAK's ROE is +0.02%, compared to PROC's ROE of -2.22%. Regarding short-term risk, TAK is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for TAK.Check PROC's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
TAK vs CPIX Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, CPIX has a market cap of 100.7M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while CPIX trades at $6.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas CPIX's P/E ratio is -16.80. In terms of profitability, TAK's ROE is +0.02%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, TAK is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for TAK.Check CPIX's competition here
OptiNose, Inc. (NASDAQ: OPTN)
TAK vs OPTN Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas OPTN's P/E ratio is -4.42. In terms of profitability, TAK's ROE is +0.02%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, TAK is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for TAK.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
TAK vs ZOM Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas ZOM's P/E ratio is -1.62. In terms of profitability, TAK's ROE is +0.02%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, TAK is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
TAK vs GRVI Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas GRVI's P/E ratio is 26.05. In terms of profitability, TAK's ROE is +0.02%, compared to GRVI's ROE of -4.51%. Regarding short-term risk, TAK is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for TAK.Check GRVI's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
TAK vs ZYNE Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, TAK's ROE is +0.02%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, TAK is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ZYNE's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
TAK vs ZYBT Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, ZYBT has a market cap of 69.7M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while ZYBT trades at $1.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas ZYBT's P/E ratio is -7.35. In terms of profitability, TAK's ROE is +0.02%, compared to ZYBT's ROE of -0.31%. Regarding short-term risk, TAK is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ZYBT's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
TAK vs SSIC Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas SSIC's P/E ratio is 11.93. In terms of profitability, TAK's ROE is +0.02%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, TAK is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for TAK.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
TAK vs VLNS Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas VLNS's P/E ratio is -1.03. In terms of profitability, TAK's ROE is +0.02%, compared to VLNS's ROE of N/A. Regarding short-term risk, TAK is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for TAK.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
TAK vs DRRX Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas DRRX's P/E ratio is -4.44. In terms of profitability, TAK's ROE is +0.02%, compared to DRRX's ROE of -0.70%. Regarding short-term risk, TAK is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for TAK.Check DRRX's competition here
Talphera, Inc. (NASDAQ: TLPH)
TAK vs TLPH Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, TLPH has a market cap of 56.1M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while TLPH trades at $1.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas TLPH's P/E ratio is -4.00. In terms of profitability, TAK's ROE is +0.02%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, TAK is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for TAK.Check TLPH's competition here
InterCure Ltd. (NASDAQ: INCR)
TAK vs INCR Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, INCR has a market cap of 52.8M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while INCR trades at $4.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas INCR's P/E ratio is -4.69. In terms of profitability, TAK's ROE is +0.02%, compared to INCR's ROE of -0.09%. Regarding short-term risk, TAK is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for TAK.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
TAK vs JUPW Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas JUPW's P/E ratio is -2.41. In terms of profitability, TAK's ROE is +0.02%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, TAK is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for TAK.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
TAK vs QLI Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas QLI's P/E ratio is -4.92. In terms of profitability, TAK's ROE is +0.02%, compared to QLI's ROE of -0.16%. Regarding short-term risk, TAK is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for TAK.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
TAK vs HEXO Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas HEXO's P/E ratio is -0.26. In terms of profitability, TAK's ROE is +0.02%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, TAK is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for TAK.Check HEXO's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
TAK vs RMTI Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, RMTI has a market cap of 30.3M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while RMTI trades at $7.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas RMTI's P/E ratio is -5.61. In terms of profitability, TAK's ROE is +0.02%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, TAK is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for TAK.Check RMTI's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
TAK vs CPHI Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, CPHI has a market cap of 29.5M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while CPHI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas CPHI's P/E ratio is -1.59. In terms of profitability, TAK's ROE is +0.02%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, TAK is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for TAK.Check CPHI's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
TAK vs CYTH Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas CYTH's P/E ratio is -0.80. In terms of profitability, TAK's ROE is +0.02%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, TAK is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for TAK.Check CYTH's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
TAK vs SHPH Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, SHPH has a market cap of 22.7M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while SHPH trades at $4.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas SHPH's P/E ratio is -0.22. In terms of profitability, TAK's ROE is +0.02%, compared to SHPH's ROE of -1.57%. Regarding short-term risk, TAK is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for TAK.Check SHPH's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
TAK vs TXMD Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, TXMD has a market cap of 21.5M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while TXMD trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas TXMD's P/E ratio is 94.83. In terms of profitability, TAK's ROE is +0.02%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, TAK is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for TAK.Check TXMD's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
TAK vs AYTU Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, AYTU has a market cap of 21.3M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while AYTU trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas AYTU's P/E ratio is -1.66. In terms of profitability, TAK's ROE is +0.02%, compared to AYTU's ROE of -0.53%. Regarding short-term risk, TAK is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for TAK.Check AYTU's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
TAK vs EVOK Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas EVOK's P/E ratio is -7.97. In terms of profitability, TAK's ROE is +0.02%, compared to EVOK's ROE of -0.70%. Regarding short-term risk, TAK is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for TAK.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
TAK vs OPTH Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, OPTH has a market cap of 18.8M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while OPTH trades at $3.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas OPTH's P/E ratio is -2.10. In terms of profitability, TAK's ROE is +0.02%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, TAK is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for TAK.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
TAK vs ACRX Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas ACRX's P/E ratio is -0.31. In terms of profitability, TAK's ROE is +0.02%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, TAK is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ACRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
TAK vs CABR Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, CABR has a market cap of 10.9M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while CABR trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas CABR's P/E ratio is -1.54. In terms of profitability, TAK's ROE is +0.02%, compared to CABR's ROE of -3.86%. Regarding short-term risk, TAK is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for TAK.Check CABR's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
TAK vs AGRX Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas AGRX's P/E ratio is -0.89. In terms of profitability, TAK's ROE is +0.02%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, TAK is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for TAK.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
TAK vs NLTX Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas NLTX's P/E ratio is -0.28. In terms of profitability, TAK's ROE is +0.02%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, TAK is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for TAK.Check NLTX's competition here
InMed Pharmaceuticals Inc. (NASDAQ: INM)
TAK vs INM Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, INM has a market cap of 7.6M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while INM trades at $1.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas INM's P/E ratio is -0.45. In terms of profitability, TAK's ROE is +0.02%, compared to INM's ROE of -1.35%. Regarding short-term risk, TAK is less volatile compared to INM. This indicates lower risk in terms of short-term price fluctuations for TAK.Check INM's competition here
Lannett Company, Inc. (NYSE: LCI)
TAK vs LCI Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas LCI's P/E ratio is -0.04. In terms of profitability, TAK's ROE is +0.02%, compared to LCI's ROE of +1.66%. Regarding short-term risk, TAK is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for TAK.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
TAK vs ADMP Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas ADMP's P/E ratio is -0.08. In terms of profitability, TAK's ROE is +0.02%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, TAK is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for TAK.Check ADMP's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
TAK vs SNOA Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, SNOA has a market cap of 5.4M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while SNOA trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas SNOA's P/E ratio is -1.01. In terms of profitability, TAK's ROE is +0.02%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, TAK is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for TAK.Check SNOA's competition here
Mallinckrodt plc (AMEX: MNK)
TAK vs MNK Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas MNK's P/E ratio is -0.44. In terms of profitability, TAK's ROE is +0.02%, compared to MNK's ROE of -0.36%. Regarding short-term risk, TAK is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for TAK.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
TAK vs FLGC Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas FLGC's P/E ratio is -0.19. In terms of profitability, TAK's ROE is +0.02%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, TAK is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for TAK.Check FLGC's competition here
cbdMD, Inc. (AMEX: YCBD)
TAK vs YCBD Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, YCBD has a market cap of 4M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while YCBD trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas YCBD's P/E ratio is -0.87. In terms of profitability, TAK's ROE is +0.02%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, TAK is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for TAK.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
TAK vs GELS Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, GELS has a market cap of 3.9M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while GELS trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas GELS's P/E ratio is -0.98. In terms of profitability, TAK's ROE is +0.02%, compared to GELS's ROE of -0.36%. Regarding short-term risk, TAK is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for TAK.Check GELS's competition here
Akanda Corp. (NASDAQ: AKAN)
TAK vs AKAN Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, AKAN has a market cap of 2.7M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while AKAN trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas AKAN's P/E ratio is -0.02. In terms of profitability, TAK's ROE is +0.02%, compared to AKAN's ROE of +3.92%. Regarding short-term risk, TAK is less volatile compared to AKAN. This indicates lower risk in terms of short-term price fluctuations for TAK.Check AKAN's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
TAK vs PLXP Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas PLXP's P/E ratio is -0.22. In terms of profitability, TAK's ROE is +0.02%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, TAK is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for TAK.Check PLXP's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
TAK vs UPC Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, UPC has a market cap of 2.5M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while UPC trades at $3.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas UPC's P/E ratio is -0.48. In terms of profitability, TAK's ROE is +0.02%, compared to UPC's ROE of -0.03%. Regarding short-term risk, TAK is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for TAK.Check UPC's competition here
Athenex, Inc. (NASDAQ: ATNX)
TAK vs ATNX Comparison October 2026
Takeda Pharmaceutical Company Limited (NYSE: TAK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TAK stands at 62.4B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, TAK is priced at $19.61 on the NYSE, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TAK currently has a P/E ratio of 14.10, whereas ATNX's P/E ratio is -0.02. In terms of profitability, TAK's ROE is +0.02%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, TAK is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for TAK.Check ATNX's competition here